The profound variability in human physiological reactions to identical environmental challenges, starkly highlighted by the recent global SARS-CoV-2 pandemic, has long presented a fundamental enigma in medical science. While some individuals navigate pathogen exposure with minimal symptoms, others succumb to severe illness, raising crucial questions about the underlying determinants of such disparate outcomes. A groundbreaking investigation led by researchers at the Salk Institute has now meticulously cataloged the intricate molecular mechanisms through which both genetic predispositions and accumulated life experiences distinctly sculpt the human immune system, offering unprecedented insights into this perplexing diversity.
Published in Nature Genetics on January 27, 2026, this landmark study unveils a sophisticated epigenetic database that delineates how inherited characteristics and an individual’s unique journey through life—encompassing infections, vaccinations, and environmental exposures—imprint enduring modifications on different immune cell types. This comprehensive, cell type-specific inventory not only elucidates the molecular underpinnings of varying immune responses but also charts a promising course toward the development of highly personalized medical interventions.
At the heart of this biological puzzle lies the epigenome, a dynamic layer of chemical modifications that sits atop our DNA. While every somatic cell in the human body harbors an identical genetic blueprint, their vastly diverse forms and functions—from a neuron’s signaling to an immune cell’s pathogen-fighting—are largely orchestrated by these epigenetic markers. These molecular tags, primarily in the form of DNA methylation, act as intricate switches, dictating which genes are actively expressed or silenced within a given cell, without altering the underlying DNA sequence itself. Unlike the static genome, the epigenome is inherently plastic, continuously adapting throughout an organism’s lifespan in response to both intrinsic genetic instructions and extrinsic environmental cues.
"Our immune cells serve as living archives, meticulously recording the interplay between our genetic heritage and the totality of our life experiences, and these two powerful forces exert markedly different influences on immune system architecture," remarked Dr. Joseph Ecker, a distinguished professor, Salk International Council Chair in Genetics, and Howard Hughes Medical Institute investigator, who served as the study’s senior author. "This research unequivocally demonstrates that encounters with pathogens and various environmental agents leave indelible epigenetic signatures that profoundly impact subsequent immune cell behavior. By dissecting these effects at the single-cell type level, we can now begin to forge direct connections between specific genetic and epigenetic risk factors and the precise immune cells where the genesis of disease truly commences."
The long-standing "nature versus nurture" debate, a cornerstone of biological inquiry, finds a compelling new dimension within the context of immunology. While genetic inheritance (nature) provides the foundational blueprint for immune components, life experiences (nurture) fine-tune their operation. Historically, disentangling the precise contributions of these two forces to immune cell function has been a formidable challenge. This Salk team’s pioneering work directly addresses this by distinguishing between epigenetic changes primarily driven by genetic inheritance (gDMRs, or genetically inherited differentially methylated regions) and those predominantly shaped by life experiences (eDMRs, or experience-driven differentially methylated regions).
To achieve this granular distinction, the research team undertook an ambitious analysis of blood samples collected from 110 individuals, carefully selected to represent a broad spectrum of genetic diversity and experiential histories. This diverse cohort offered a rich tapestry of immune imprints, reflecting past exposures to common pathogens like influenza, HIV-1, methicillin-resistant Staphylococcus aureus (MRSA), methicillin-sensitive Staphylococcus aureus (MSSA), and SARS-CoV-2. The study also accounted for significant medical interventions, such as anthrax vaccination, and environmental exposures, including organophosphate pesticides. This comprehensive dataset allowed the scientists to build a robust molecular record of how various life events subtly, yet profoundly, reconfigure the epigenetic landscape of immune cells.
The investigation focused on four principal types of immune cells, each playing a distinct role in the body’s defense mechanisms. T cells and B cells, key players in the adaptive immune system, are renowned for their capacity to develop and retain long-term immunological memory, enabling a swift and potent response upon re-encountering a familiar threat. In contrast, monocytes and natural killer (NK) cells belong to the innate immune system, serving as immediate responders that rapidly detect and neutralize a wide array of perceived dangers. By meticulously comparing the epigenetic patterns—specifically, the differentially methylated regions (DMRs)—across these distinct cell populations, the team constructed an unparalleled, cell type-specific catalog of epigenetic markers.
"Our findings reveal that genetic variants associated with disease often exert their influence by modulating DNA methylation in very specific immune cell types," explained Dr. Wubin Ding, a postdoctoral fellow in Dr. Ecker’s laboratory and a co-first author of the study. "By precisely mapping these intricate connections, we gain the capability to pinpoint which cellular populations and molecular signaling pathways are implicated by disease susceptibility genes, thereby potentially opening entirely new avenues for the development of more targeted and effective therapeutic strategies."
A pivotal methodological breakthrough of this study was the ability to systematically segregate and characterize gDMRs and eDMRs. The researchers observed a striking spatial segregation in the epigenome for these two categories of modifications. Epigenetic changes directly attributable to genetic inheritance tended to cluster within stable, evolutionarily conserved gene regions, a pattern particularly pronounced in the long-lived T and B lymphocytes that underpin immunological memory. Conversely, epigenetic modifications arising from life experiences were predominantly concentrated in more flexible, dynamic regulatory regions of the genome. These regions are critical for controlling rapid and adaptive immune responses, allowing cells to swiftly adjust their gene expression profiles in response to immediate environmental cues.
This distinct localization suggests a sophisticated division of labor: inherited genetics appear to establish the fundamental, long-term programs and baseline functionalities of the immune system, providing a stable framework for defense. Life experiences, meanwhile, act as powerful fine-tuners, enabling immune cells to calibrate and optimize their reactions to specific, encountered situations. While these patterns offer compelling insights, further mechanistic research will be indispensable to fully unravel how these interwoven influences ultimately dictate immune performance, both in states of health and during disease.
"Our meticulously constructed human population immune cell atlas promises to be an invaluable resource for future mechanistic investigations into both infectious and genetic diseases, extending its utility to diagnostic and prognostic applications," stated Dr. Manoj Hariharan, a senior staff scientist in Dr. Ecker’s lab and another co-first author. "Frequently, when individuals fall ill, the precise etiology or the potential trajectory of their condition remains unclear. The detailed epigenetic signatures we have developed offer a sophisticated molecular roadmap to classify and accurately assess such complex clinical scenarios."
The ramifications of these findings are profound, underscoring the formidable influence that both one’s genetic endowment and cumulative life history exert on immune cell identity and the overall behavior of the immune system. The newly established epigenetic catalog serves as a critical foundational framework for pioneering highly personalized approaches to disease prevention and treatment.
Dr. Ecker highlighted the transformative potential of this evolving database. As it continues to expand with the inclusion of additional patient samples, it could fundamentally alter how clinicians predict individual susceptibilities and responses to future infections. For instance, if a sufficient volume of data from COVID-19 survivors reveals a shared, protective eDMR, medical professionals could potentially analyze a newly infected patient’s immune cells to ascertain the presence or absence of this specific protective marker. Should it be absent, scientists could then strategically target related regulatory pathways, aiming to enhance the patient’s immune response and improve clinical outcomes.
"Our extensive work lays a robust foundation for the development of precision prevention strategies specifically tailored for infectious diseases," affirmed Dr. Wenliang Wang, a staff scientist in Dr. Ecker’s lab and a co-first author. "For prevalent infections such as COVID-19 or influenza, and countless others, we envision a future where, as research cohorts and predictive models continue to advance, we may be able to forecast an individual’s likely reaction to an infection even prior to exposure. Instead, by analyzing their genome, we could predict how the infection will impact their epigenome, and subsequently, how those specific epigenetic alterations will influence their symptom presentation and disease severity."
This monumental undertaking was a collaborative effort involving numerous distinguished scientists. Other contributing authors include Anna Bartlett, Cesar Barragan, Rosa Castanon, Vince Rothenberg, Haili Song, Joseph Nery, Jordan Altshul, Mia Kenworthy, Hanqing Liu, Wei Tian, Jingtian Zhou, Qiurui Zeng, and Huaming Chen from the Salk Institute; Andrew Aldridge, Lisa L. Satterwhite, Thomas W. Burke, Elizabeth A. Petzold, and Vance G. Fowler Jr. of Duke University; Bei Wei and William J. Greenleaf of Stanford University; Irem B. Gündüz and Fabian Müller of Saarland University; Todd Norell and Timothy J. Broderick of the Florida Institute for Human and Machine Cognition; Micah T. McClain and Christopher W. Woods of Duke University and Durham Veterans Affairs Medical Center; Xiling Shen of the Terasaki Institute for Biomedical Innovation; Parinya Panuwet and Dana B. Barr of Emory University; Jennifer L. Beare, Anthony K. Smith, and Rachel R. Spurbeck of Battelle Memorial Institute; Sindhu Vangeti, Irene Ramos, German Nudelman, and Stuart C. Sealfon of Icahn School of Medicine at Mount Sinai; Flora Castellino of the US Department of Health and Human Services; and Anna Maria Walley and Thomas Evans of Vaccitech plc.
Financial support for this extensive research was generously provided by the Defense Advanced Research Projects Agency (N6600119C4022) through the US Army Research Office (W911NF-19-2-0185), the National Institutes of Health (P50-HG007735, UM1-HG009442, UM1-HG009436, 1R01AI165671), and the National Science Foundation (1548562, 1540931, 2005632).
About the Author
